While the new Shield blood test may motivate more people to get screened for colorectal cancer, it also comes with downsides, ...
which gained FDA approval in July as a primary screening option for colorectal cancer in average-risk adults who are age 45 ...
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...
New data from cancer screening and diagnostic test provider Exact Sciences have shown an 88.3% sensitivity rate for its blood-based colorectal cancer screening test.
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
“A blood-based colorectal cancer screening test that can detect advanced precancerous lesions ... Exact Sciences plans to use these results to support an FDA submission and approval and to ...
Blood tests for cancer detection, known as liquid biopsies, can still be unreliable, but progress is being made. Competition between different diagnostics companies is also intensifying.
The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...
Many people are simply unaware of the existence of the FIT test or underestimate its importance in colorectal cancer ...
Recommended Reading Guardant wins FDA approval for colon cancer blood test ... Administration submission for the blood-based test. Blood tests to detect cancer are intended to boost screening ...